Sarepta Therapeutics' Experimental siRNA Therapies Show Promising Early Results, Shares Surge 26%

Sarepta Therapeutics reported positive early clinical results for its siRNA therapies SRP-1001 and SRP-1003, showing dose-dependent muscle exposure and favorable tolerability for neuromuscular diseases. The Phase 1/2 studies demonstrated high concentrations in muscle tissue without dose-limiting toxicity and proof-of-concept evidence that a single dose can reduce target protein or mRNA levels. Jefferies analysts highlighted the positive results, noting they partially de-risk the broader siRNA platform and may support stock upside of 15% to 30%.